During Monday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about the prospects for CRISPR Therapeutics (CRSP) : "A company like this isn't bought on earnings, it's bought on speculation. As long as you're OK with that, I'll bless it," responded Cramer.
More from Investing
The strength in the Russell 2000 is a positive sign for stock-picking.
Amid the Fed's shift in tone and the market's reaction, I'm eyeing Apex Technology Acquisition.
Here's what Jim Cramer has to say about the stock.
While the Fed hasn't made any actual rate policy changes, seven Fed members are now predicting a hike in 2022 vs. four previously.